% 0期刊文章% Lars Høj Markvardsen %一个Søren Sindrup %一个Ingelise克里斯琴森%一个约翰内斯·雅各布森尼尔斯·奥尔森Kjær % % Henning安徒生% T皮下免疫球蛋白在首次治疗患者的一线治疗慢性炎性脱髓鞘多神经病——个随机对照试验研究(S45.003) % D J神经病学2017% % P S45.003 X % V % 88% N 16补充目的:调查是否有多个皮下注入传统疗法一样有效的静脉加载剂量在首次治疗CIDP患者。首页背景:皮下免疫球蛋白(SCIG)是有效的维持治疗在慢性炎性脱髓鞘多神经病(CIDP)。设计/方法:20例full-filling CIDP的临床和电生理标准包括,对待SCIG 0.4克* 1公斤−−1 *周5周或丙种球蛋白0.4克* 1公斤−−1 *天5天。治疗10周后患者转向相反的胳膊,然后进一步10周。所有参与者评估周0、2、5和10在治疗。主要结果是结合等速肌力(cik)。二次结果残疾,临床评价的肌肉力量和各种功能测试的性能。结果:所有的参与者都收到疗法,十四完成协议。总的来说,cik增加了在SCIG 7.4±14.5% (p = 0.0003)和6.9±16.8% (p = 0.002)在丙种球蛋白,效果相似(p = 0.80)。改善cik丙种球蛋白两周后达到峰值10.2±17.0% (p < 0.05)和5周后SCIG 11.2±17.1% (p < 0.05)。残疾改善SCIG治疗期间。肌肉力量由人工肌肉测试改进后5和10周期间SCIG但只有5周后在丙种球蛋白。 The remaining parameters improved equally during both treatments. P-IgG levels at baseline and improvement of cIKS were related.Conclusions: In treatment-naïve CIDP patients short-lasting SCIG and IVIG therapy improve motor performance to a similar degree, but with earlier maximal improvement following IVIG than SCIG treatment.In addition low P-IgG levels is associated with a better outcome for cIKS.Study Supported by: Sponsored by CSL BehringDisclosure: Dr. Markvardsen has received personal compensation for activities with Octapharma Pharmaceuticals as a speaker. Dr. Markvardsen has received research support from Octapharma Pharmaceuticals. Dr. Sindrup has nothing to disclose. Dr. Christiansen has nothing to disclose. Dr. Olsen has nothing to disclose. Dr. Jakobsen has nothing to disclose. Dr. Andersen has nothing to disclose. %U

map